{
    "clinical_study": {
        "@rank": "78883", 
        "biospec_descr": {
            "textblock": "Boold,Urine"
        }, 
        "biospec_retention": "Samples Without DNA", 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the effectiveness and security of lobaplatin\n      combined with docetaxel in treatment of the sensitive recurrent ovarian cancer."
        }, 
        "brief_title": "A Study of Docetaxel and Lobaplatin Versus Docetaxel and Carboplatin Combination Regimen in Patients With Platinum-sensitive (>6 Months) Relapsed Ovarian Cancer", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Recurrent Ovarian Cancer", 
        "condition_browse": {
            "mesh_term": "Ovarian Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. age between 18 and  70 years old\n\n          2. singed the information consent form\n\n          3. Expected survival time >3 months\n\n          4. Recurrence for at least 6 months after receiving initial platinum-based chemotherapy\n             and without cytoreductive surgery indications.\n\n        Exclusion Criteria:\n\n          1. Recurrence within 6 months after receiving initial platinum-based chemotherapy\n\n          2. without radiographic evidence for tumor recurrence\n\n          3. receiving other chemotherapy, hormone therapy, immunotherapy, or radiation therapy"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "residents of a certain town"
            }
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01851746", 
            "org_study_id": "CHB2013"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Docetaxel", 
                "Carboplatin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "recurrent ovarian cancer", 
            "lobaplatin", 
            "docetaxel", 
            "carboplatin"
        ], 
        "lastchanged_date": "May 9, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Wuhan", 
                    "country": "China", 
                    "state": "Hubei", 
                    "zip": "430071"
                }, 
                "name": "Zhongnan Hospital of Wuhan University"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_groups": "1", 
        "official_title": "A Study of Docetaxel and Lobaplatin vs. Docetaxel and Carboplatin Combination Regimen in Patients With Platinum-sensitive (>6 Months) Relapsed Ovarian Cancer", 
        "overall_official": {
            "affiliation": "Wuhan University", 
            "last_name": "Hong-bing Cai, MD,PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "China: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Blood routine, urine routine,  hepatic and kidney function, electrolyte, ECG, CT,MRI", 
            "measure": "Evidence of  the effectiveness and security of lobaplatin combined with docetaxel in treatment of the sensitive recurrent ovarian cancer.", 
            "safety_issue": "Yes", 
            "time_frame": "from pre-chemotherapy to 4-6 weeks post-chemotherapy"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01851746"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Wuhan University", 
            "investigator_full_name": "HB Cai", 
            "investigator_title": "Director of gynecologic oncology department of Zhongnan Hospital of Wuhan University", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Wuhan University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Wuhan University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Observational Model: Case Control, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2013"
    }
}